latest update:
[TrialBase DB]

trial summary · NCT07757802

Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

A Clinical Trial to Evaluate the Safety and Immunogenicity of ACU-026-001-1-Adjuvanted CH505 Protein Nanoparticles (DV901-NP) Alone or Boosted With CH505 NP (DV902-NP) or CH505 mRNAs in Adults in Overall Good Health Without HIV

Trial record from the TrialBase DB dataset, status RECRUITING, condition HIV, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07757802phase PHASE1enrollment 54start 2026-12-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This Phase 1 study will evaluate the safety, tolerability, and immune responses of investigational CH505 HIV vaccine regimens in adults in overall good health without HIV. Participants will receive CH505 protein nanoparticle vaccines (DV901-NP) formulated with the investigational adjuvant ACU-026-001-1, followed by either CH505 protein nanoparticle (DV902-NP) or CH505 mRNA vaccine boosters. The study will assess the ability of these regimens to induce HIV-specific immune responses, including B-cell responses associated with the development of broadly neutralizing antibodies. An immunology cohort will also evaluate how the location of booster vaccination affects immune responses.

Source record: https://clinicaltrials.gov/study/NCT07757802

Facts

registry idNCT07757802
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionHIV
sponsorNational Institute of Allergy and Infectious Diseases (NIAID)
sponsor classNIH
enrollment54
start date2026-12-01
primary completion2028-06-07
completion2028-10-07
results postednot reported

Conditions

  • HIV

Interventions

  • DV901-NP
  • DV902-NP
  • CH505 TF mRNA-gp160
  • CH505 w24 mRNA-gp160
  • ACU-026-001-1

Countries

  • United States

Intervention types: BIOLOGICAL

Work with this record